Johnson and Johnson: Darzalex-SC Based Quadruplet Regimen Approved by the European Commission for Patients With Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible
October 24, 2024
October 24, 2024
NEW BRUNSWICK, New Jersey, Oct. 24 (TNSres) -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent reduction in risk of disease progression or death/1
New regimen rei . . .
* * *
Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent reduction in risk of disease progression or death/1
New regimen rei . . .